
Content
A Durolane hip injection is a single 3 mL dose (60 mg) of stabilized, non-animal hyaluronic acid placed into the hip joint under ultrasound or fluoroscopic guidance to ease osteoarthritis pain. Whether it brings comfort depends on where you are and what evidence you weigh: in the United States the FDA approved Durolane only for knee osteoarthritis, so a hyaluronic acid hip injection with Durolane is off-label there, while Canadian and European labeling include the hip.
The clinical evidence is mixed. Open studies report that many patients feel better after a single injection, but the one randomized trial that tested Durolane in the hip against saline found no meaningful benefit, and both the AAOS and the ACR advise against hyaluronic acid for hip osteoarthritis. A Durolane injection in the hip is therefore a judgment call for a specialist, not a routine first step.
This guide is written for licensed practitioners and clinic buyers, with plain-language notes for patients. For the product basics (composition, dosing, how NASHA gel works), see our overview what Durolane is and how it is used.
Durolane’s regulatory status for hip arthritis is not the same everywhere, and this is the single most important point for any clinic that stocks it.
United States. Durolane is a Class III device approved through the FDA premarket approval P170007 in August 2017. Its indication is pain in osteoarthritis of the knee in patients who have not responded adequately to conservative non-drug therapy or simple analgesics such as acetaminophen. The labeling is explicit about other joints:
“The safety and effectiveness of DUROLANE® in joints other than the knee have not been studied.” FDA, Durolane Instructions for Use (PMA P170007)
A US physician may still choose to use Durolane in the hip as off-label practice, but the patient should be told so, and payers generally do not cover it: Medicare local coverage policies such as Palmetto GBA’s LCD L39260 are written for hyaluronic acid injections in knee osteoarthritis only.
Canada. The Canadian labeling published by Bioventus includes the hip:
“DUROLANE is indicated for the symptomatic treatment of mild to moderate knee or hip osteoarthritis.” Bioventus, DUROLANE Canada, Summary of Indications for Use
The Canadian instructions for use add the ankle, fingers and toes, and pain after arthroscopy in an osteoarthritic joint within 3 months of the procedure. The recommended dose is the full 3 mL syringe for a knee or hip joint.
European Union and other markets. According to the manufacturer’s international summary of indications, the EU labeling also covers mild to moderate knee or hip osteoarthritis, and in the EU, Australia and New Zealand it extends to the ankle, shoulder, elbow, wrist, fingers and toes. That is why patients in the Netherlands and Belgium searching for “Durolane infiltraties” in the hip are reading about an on-label use in their country. Mexico and Taiwan, by contrast, list the knee only.
Durolane is made with NASHA technology: hyaluronic acid produced by bacterial fermentation and lightly stabilized into a gel at 20 mg/mL. It is not synthetic, not animal-derived and not a steroid. The stabilization is intended to keep the gel in the joint longer than an unmodified sodium hyaluronate solution, which is why one injection replaces the three to five weekly shots that older products require.
In an osteoarthritic hip, the synovial fluid loses viscosity and elasticity. The rationale for viscosupplementation is to restore some of that cushioning and lubrication and to dampen pain signaling for several months. That rationale is better supported in the knee than in the hip. Earlier versions of this page claimed that Durolane can slow the progression of hip osteoarthritis; no randomized trial has shown that, and the FDA labeling makes no such claim.
The practical appeal is one visit, one injection and no steroid exposure. Licensed buyers can order Durolane 60 mg/3 mL or view the full Durolane brand page through a verified OGOmed account.
Orthopedics products
17 products available
Explore our Orthopedics products collection and browse available products.
View category
Searches for “Durolane hip injection reviews” and “Durolane injection success rate” usually lead to open, uncontrolled reports. Those results look encouraging, but in hip osteoarthritis a saline injection alone often produces a clinically noticeable improvement, so controlled trials matter most.
| Study | Design and patients | Main result |
|---|---|---|
| Berg and Olsson, 2004 | Open pilot, 31 hips, single NASHA injection | Response rate 50% at 2 weeks and 54% at 3 months; no control group |
| Conrozier et al., 2009 | Open follow-up in daily practice, 40 patients, fluoroscopy-guided | 71% met OMERACT-OARSI responder criteria; 15 of 28 had a transient pain increase in the first week |
| Atchia et al., 2011 | Randomized, 77 patients: Durolane vs saline vs methylprednisolone vs no injection, ultrasound-guided | Responders: steroid 74%, saline 21%, Durolane 11%, no injection 10% |
| Long and Fitzpatrick, 2021 | Case series, 87 patients with mild to moderate hip OA, ultrasound-guided Durolane | Modified Harris Hip Score rose from 58.5 to 71.3 at 6 weeks; no control group |
| Gazendam et al., 2021 | Network meta-analysis, 11 RCTs, 1,353 patients | No injection (steroid, HA, PRP) outperformed saline for pain or function up to 6 months |
| Liu et al., 2026 | Network meta-analysis, 14 studies, 1,254 patients | No injection type differed significantly from standard care or placebo at 3, 6 or 12 months |
The open studies came first. A Swedish pilot published in Clinical and Experimental Rheumatology (2004) and a French practice-based series in Archives of Orthopaedic and Trauma Surgery (2009) both reported responder rates above 50%, and both authors called for controlled trials. A more recent Australian case series of 87 patients, published in BMC Musculoskeletal Disorders (2021), found an improvement that exceeded the minimal clinically important difference at 6 weeks; one author disclosed prior membership of a Bioventus advisory board.
The only randomized trial of Durolane in the hip tells a different story. In the study by Atchia and colleagues, published in Annals of the Rheumatic Diseases (2011), patients with moderate to severe hip osteoarthritis received a single ultrasound-guided injection. Only the corticosteroid group improved significantly; Durolane performed no better than saline or no injection. The trial was small, and it enrolled more advanced disease than the labeling targets, so it does not settle the question for mild to moderate hips.
Pooled analyses lean the same way. A 2018 meta-analysis of eight randomized trials (807 patients) in Archives of Physical Medicine and Rehabilitation found no evidence that hyaluronic acid beats placebo for hip pain at 3 months, and its authors did not recommend viscosupplementation for the hip. The network meta-analysis in the British Journal of Sports Medicine (2021) concluded that intra-articular saline performed as well as every active injection, and a 2026 update in the Orthopaedic Journal of Sports Medicine found no significant differences out to 12 months. In short, many patients do feel better after a hyaluronic acid hip injection, but controlled data do not show that the hyaluronic acid itself is responsible.
US professional guidelines are firmer about the hip than about the knee. The American Academy of Orthopaedic Surgeons published its updated hip osteoarthritis guideline in December 2023 (announced in January 2024, replacing the 2017 edition). It includes a strong recommendation that:
“intraarticular hyaluronic acid should not be considered for treatment of symptomatic OA of the hip” AAOS, Management of Osteoarthritis of the Hip Guideline Update, 2023
The AAOS gives the reason in the same recommendation: hyaluronic acid does not improve function or reduce pain better than placebo. The same update makes a moderate recommendation that intra-articular corticosteroids could be considered for short-term relief. The 2017 edition of the AAOS hip guideline had reached the same conclusion on hyaluronic acid.
The 2019 American College of Rheumatology/Arthritis Foundation guideline conditionally recommends against hyaluronic acid in the knee but strongly recommends against it in hip osteoarthritis. In ACR terms, a strong recommendation means the panel was confident the advice applies to all or almost all patients.
European experts are more favorable. The EUROVISCO group, a Delphi panel of rheumatologists and orthopedic surgeons whose 2026 hip recommendations appeared in Cartilage, supports viscosupplementation for hip osteoarthritis in patients who do not need surgery, mainly in mild to moderate disease, always under imaging guidance. This is expert consensus built partly on observational data, not a trial result.
The hip joint sits deep beneath muscle, close to the femoral artery, vein and nerve. Landmark-guided (“blind”) injections are less reliable here than in the knee, and the gel must reach the joint cavity to have any chance of working. The Canadian Durolane instructions for use therefore state that the hip injection should be given under fluoroscopic control, preferably with contrast medium, or under ultrasound control to confirm needle position.
A typical image-guided procedure in a specialist setting looks like this:
The injection itself usually takes a few minutes; most of the appointment is preparation and imaging.
Side effects in the hip are similar in type to those in the knee: local and usually short-lived. The Canadian labeling notes that most adverse reactions in knee and hip studies were transient pain, swelling or stiffness in the joint, of mild or moderate intensity. In the hip series, the pattern was consistent:
Durolane is not a steroid, and it is not made from poultry, so egg or feather allergy is not a concern. Safety in pregnancy, breastfeeding and patients aged 21 or younger has not been established. A new hot, swollen joint after any injection should be assessed for infection before it is attributed to the product. For more detail, see our article on potential side effects of Durolane.
Given the guideline position, a Durolane injection in the hip is best viewed as a selective option after shared decision-making, not a default. Patients most often considered are those with:
Patients with severe hip OA (bone-on-bone narrowing, femoral head collapse or marked deformity) are poor candidates; the most recent Durolane hip series excluded them, and the randomized trial that enrolled moderate to severe hips found no effect. Patients already scheduled for hip replacement should also wait: the EUROVISCO panel advises against arthroplasty within 3 months of a hip viscosupplement injection. In the US, every candidate should be told that hip use is off-label and that insurance is unlikely to pay for the product.
For most patients, a hyaluronic acid hip injection is not the first treatment to try. The AAOS 2023 guideline gives its strongest support to oral NSAIDs (when not contraindicated) and moderate support to physical therapy for mild to moderate disease. Other options include:
A Durolane hip injection is a reasonable option for a narrow group: patients with mild to moderate hip osteoarthritis who have tried first-line care, prefer to avoid repeated steroids, and accept that controlled trials have not shown a clear advantage over saline. Where it is labeled for the hip, as in Canada and the EU, it is an approved single-visit treatment; in the United States it remains off-label, outside AAOS and ACR recommendations and usually outside insurance coverage.
If it is used, it should be given under ultrasound or fluoroscopic guidance by a trained specialist, as part of a broader plan that includes exercise, weight management and analgesics, with realistic expectations about how long any relief may last. Viscosupplements are prescription devices and should be purchased and administered only by licensed healthcare professionals.
Last updated: November 2026.
It depends on the country. In the United States, the FDA approved Durolane only for knee osteoarthritis pain, and its labeling states that other joints have not been studied, so hip use is off-label. In Canada and the European Union, the labeling covers symptomatic treatment of mild to moderate knee or hip osteoarthritis, using the same 3 mL dose in the hip.
Response, if it comes, is usually seen within a few weeks. In an open pilot study of 31 hips, 50% of patients met the response criteria at 2 weeks and 54% at 3 months. Some patients first notice a temporary increase in hip pain during the first week, which settles. Controlled trials have not confirmed that the improvement exceeds what saline produces.
Reported success rates vary widely with study design. Open studies without a control group report responder rates of about 50% to 71%. In the only randomized trial of Durolane in the hip, 77 patients with moderate to severe osteoarthritis, just 11% responded to Durolane, compared with 21% to saline and 74% to a corticosteroid injection.
No. Durolane is stabilized sodium hyaluronate, a gel form of a substance naturally present in joint fluid, produced by bacterial fermentation. It is regulated as a medical device, not a drug, and contains no corticosteroid. In hip trials it has been compared with the steroid methylprednisolone, which gave faster and stronger short-term relief.
Only where the local labeling allows it. Durolane’s labeling in the EU, Australia and New Zealand includes osteoarthritis pain in the shoulder, elbow, wrist, ankle, fingers and toes. The Canadian labeling covers the knee, hip, ankle, fingers and toes, and the US labeling covers the knee only, so a shoulder injection in the US is off-label.